Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

Phase 1/2 Terminated 20 enrolled Incyte Corporation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.

Timeline

Start: 2010-10
Primary completion: 2011-09
Completion: 2011-10

Publications

Park EJ, Lee CW. Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies. Exp Mol Med. 2024 Feb;56(1):100-109. doi: 10.1038/s12276-023-01150-6. Epub 2024 Jan 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADERBASIB	Small molecule	300 mg	—
Background	Trastuzumab	Monoclonal antibody	—	—
Background	Vinorelbine	Small molecule	—	—

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

Summary

Timeline

Publications

Drugs

Indications